Centre National De La Recherche Scientifique

Universitè De Montpellier

Institut Curie

Abivax

Karim Chebli

Jamal Tazi

Didier Scherrer

Romain Najman

Florence Mahuteau

Michael Hahne

The present disclosure relates to the use of a compound of formula (I) or anyone of its pharmaceutically acceptable salts, in the treatment and/or prevention of an inflammatory disease; wherein: means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R&#x2033; does not exist when Q is O; R' independently represent a hydrogen atom or a group chosen among a (C-C)alkyl group, a halogen atom, a hydroxyl group, a &#x2014;COORgroup, a &#x2014;NOgroup, a &#x2014;NRRgroup, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C-C)fluoroalkyl group, a &#x2014;O&#x2014;P(&#x2550;O)&#x2014;(OR)(OR) group, a (C-C)alkoxy group and a &#x2014;CN group, and can further be a group chosen among: 

Use of quinoline derivatives for the treatment of inflammatory diseases

The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R&#x2033; does not exist when Q is O; R' independently represent a hydrogen atom or a group chosen among a (C-C)alkyl group, a halogen atom, a hydroxy! group, a &#x2014;COORgroup, a &#x2014;NO2 group, a &#x2014;NRRgroup, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (Ci-C3)fluoroalkyl group, a &#x2014;O&#x2014;P(&#x2550;O)&#x2014;(ORXOR) group, a (C-C)alkoxy group and a &#x2014;CN group, and can further be a group chosen among: (IIa), (IIIa) or anyone of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of an inflammatory disease. 

Quinoline derivatives for the treatment of inflammatory diseases

Growing community of inventors

Frontingnan, France

Karim Chebli